Stockscreener 앱 받기
7.39
1.47%
-0.11
전일 마감가:
$7.50
열려 있는:
$7.5
하루 거래량:
993.72K
Relative Volume:
0.71
시가총액:
$539.38M
수익:
-
순이익/손실:
$-86.60M
주가수익비율:
-2.6091
EPS:
-2.8324
순현금흐름:
$-67.37M
1주 성능:
-29.89%
1개월 성능:
-24.05%
6개월 성능:
+75.53%
1년 성능:
+42.39%
1일 변동 폭
$7.34
$7.5923
1주일 범위
$6.90
$9.60
52주 변동 폭
$1.45
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
명칭
Lexeo Therapeutics Inc
전화
(212) 547-9879
주소
345 PARK AVENUE SOUTH, NEW YORK
LXEO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
7.39 | 547.40M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Raymond James | Strong Buy |
| 2025-11-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-15 | 개시 | Guggenheim | Buy |
| 2025-07-31 | 개시 | Oppenheimer | Outperform |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2024-06-06 | 개시 | H.C. Wainwright | Buy |
| 2023-11-28 | 개시 | Chardan Capital Markets | Buy |
| 2023-11-28 | 개시 | JP Morgan | Overweight |
| 2023-11-28 | 개시 | Leerink Partners | Outperform |
| 2023-11-28 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-28 | 개시 | Stifel | Buy |
모두보기
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
Aug Update: Is SLAB subject to activist investor interestWeekly Investment Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aug Decliners: Will Lexeo Therapeutics Inc outperform its industry peersEarnings Risk Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Price Action: Will Lexeo Therapeutics Inc outperform its industry peersAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
LXEO: Cardiac gene therapy programs show strong efficacy, safety, and commercial readiness - TradingView — Track All Markets
Heart-disease gene therapy race heating up as Lexeo posts data - BioWorld MedTech
Lexeo Therapeutics stock falls 23% despite Cantor maintaining Overweight rating - Investing.com Canada
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 6.5%Should You Sell? - MarketBeat
Day Trade: Will Lexeo Therapeutics Inc stock outperform growth indexesJuly 2025 Setups & Safe Entry Point Alerts - Bộ Nội Vụ
H.C. Wainwright lowers Lexeo Therapeutics stock price target on PKP2 data concerns - Investing.com Canada
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com - Investing.com Canada
Aug Intraday: Will Lexeo Therapeutics Inc. stock deliver shareholder valueJuly 2025 Price Swings & Stepwise Trade Signal Guides - Bộ Nội Vụ
Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Given "Buy" Rating at Chardan Capital - MarketBeat
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright - TipRanks
Lexeo’s gene therapy shows promising results for heart condition By Investing.com - Investing.com Nigeria
Lexeo Therapeutics Reflects Structural Trends In Clinical Biotech - Kalkine Media
Update Recap: Is Lexeo Therapeutics Inc forming a bullish divergenceDay Trade & Safe Capital Growth Plans - baoquankhu1.vn
Lexeo Therapeutics (NASDAQ:LXEO) Shares Gap DownHere's What Happened - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
Lexeo Therapeutics Reports Positive Interim HEROIC-PKP2 Trial Results - TipRanks
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 - TradingView — Track All Markets
Lexeo Therapeutics stock falls after PKP2 gene therapy data By Investing.com - Investing.com Canada
Lexeo Therapeutics stock falls after PKP2 gene therapy data - Investing.com
Lexeo’s gene therapy shows promising results for heart condition - Investing.com
Lexeo Therapeutics Reports Positive Interim Results from HEROIC-PKP2 Trial of LX2020 for Arrhythmogenic Cardiomyopathy - Quiver Quantitative
Lexeo Therapeutics Announces Positive Interim Phase I/II - GlobeNewswire
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Up 9% – Here’s Why - Defense World
Institutional investors have a lot riding on Lexeo Therapeutics, Inc. (NASDAQ:LXEO) with 56% ownership - simplywall.st
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 EndofMonth & AI Forecast Swing Trade Picks - Улправда
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO) and Xenon (XENE) - The Globe and Mail
Lexeo Therapeutics (NASDAQ:LXEO) Trading Up 9%Still a Buy? - MarketBeat
Why Lexeo Therapeutics Inc. stock remains a top recommendationJuly 2025 WrapUp & Safe Capital Preservation Plans - Улправда
Why Lexeo Therapeutics Inc. stock appeals to analystsWeekly Risk Report & Advanced Technical Analysis Signals - Улправда
Why Lexeo Therapeutics Inc. stock attracts global investors2025 Market Overview & Fast Entry High Yield Stock Tips - ulpravda.ru
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Explore Targeted Cardiac Delivery of Aav Gene Therapy - marketscreener.com
Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology - Quiver Quantitative
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy - GlobeNewswire
Wall Street rallies behind Lexeo Therapeutics (LXEO)’s gene therapy pipeline - MSN
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 5.5%What's Next? - MarketBeat
Contrasting Lexeo Therapeutics (NASDAQ:LXEO) and Wellgistics Health (NASDAQ:WGRX) - Defense World
Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5%Here's What Happened - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline - Insider Monkey
Lexeo Therapeutics CEO R. Nolan Townsend to Present at J.P. Morgan Healthcare Conference 2026 in San Francisco - Quiver Quantitative
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Genetic medicine firm Lexeo joins speakers at major J.P. Morgan event - Stock Titan
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Biotechnology Select Industry Index - marketscreener.com
What dividend safety score for Lexeo Therapeutics Inc. stockGap Down & Low Drawdown Trading Strategies - Улправда
Why Lexeo Therapeutics Inc stock is a must watch in 2025Quarterly Risk Review & High Conviction Buy Zone Alerts - moha.gov.vn
Is Lexeo Therapeutics Inc. stock near bottom after declineTrade Risk Report & High Accuracy Investment Signals - Улправда
Lexeo Therapeutics Earnings Notes - Trefis
Lexeo Therapeutics Inc (LXEO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lexeo Therapeutics Inc 주식 (LXEO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
4.73%
0.92%
자본화:
|
볼륨(24시간):